Amgen and Molecular Partners announce strategic collaboration in immuno-oncology
Amgen and Molecular Partners announced a collaboration and license agreement for clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells. December 19, 2018